Daiichi Sankyo: all 498 studies

Page 5 of 5. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.

• Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)TerminatedNCT01512199Phase 1/2
• A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)CompletedNCT01468467Phase 1
• A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT01390337Phase 1
• Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant TumorsCompletedNCT01364844Phase 1
• Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving MethotrexateCompletedNCT01329991Phase 1
• Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant TumorsCompletedNCT01290471Phase 1
• Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy SubjectsCompletedNCT01287858Phase 1
• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult VolunteersCompletedNCT01282684Phase 1
• Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid TumorsWithdrawnNCT01245543Phase 1
• Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)WithdrawnNCT01151592Phase 4
• Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid TumorsCompletedNCT01149720Phase 1
• The Confirmatory Olmesartan Plaque Regression StudyTerminatedNCT01132768Phase 4
• Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other TreatmentsCompletedNCT01124630Phase 1
• Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood PressureCompletedNCT01101009Phase 4
• Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving MethotrexateWithdrawnNCT01090570Phase 1
• Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid TumorsCompletedNCT01049893Phase 1
• An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid TumorsCompletedNCT01040312
• An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)CompletedNCT01039506
• CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)CompletedNCT00991796Phase 2
• CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With OxaliplatinTerminatedNCT00969033Phase 2
• Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic NephropathyCompletedNCT00914524Phase 2
• Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic SyndromeCompletedNCT00891267Phase 3
• Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential HypertensionCompletedNCT00872586Phase 3
• Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential HypertensionCompletedNCT00856271Phase 3
• Effects of Multiple Doses of CS-8080 in Healthy VolunteersTerminatedNCT00796575Phase 1
• Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media in ChildrenCompletedNCT00781521Phase 3
• Vascular Improvement With Olmesartan Medoxomil StudyCompletedNCT00772499Phase 4
• A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.CompletedNCT00755352Phase 4
• A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.CompletedNCT00754507Phase 4
• Study to Compare Welchol and TriCor to TriCor Alone in Patients With High CholesterolCompletedNCT00754039Phase 4
• A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.CompletedNCT00753779Phase 4
• Isolated Systolic Hypertension in the Elderly and Very ElderlyCompletedNCT00751829Phase 3
• Olmesartan Medoxomil Versus Losartan in Elderly and Very ElderlyCompletedNCT00751751Phase 3
• Phase I Study of U3P1287/01, Including Patients With Advanced Solid TumorsCompletedNCT00730470Phase 1
• Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24TerminatedNCT00679484Phase 3
• Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial ProtectionCompletedNCT00676845Phase 3
• 12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis PatientsCompletedNCT00616733Phase 1
• Effects of CS-8080 in Healthy VolunteersCompletedNCT00613431Phase 1
• Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 DiabetesCompletedNCT00575874Phase 2
• Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 DiabetesCompletedNCT00575471Phase 2
• Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary TractTerminatedNCT00422877Phase 2
• A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established AtherosclerosisCompletedNCT00382213Phase 3
• Olmesartan Medoxomil and Diabetic NephropathyCompletedNCT00362960Phase 3
• Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes MellitusCompletedNCT00361153Phase 2
• The Efficacy Study of Sodium Hyaluronate to Treat Symptomatic Hip OsteoarthritisTerminatedNCT00330135Phase 3
• Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)CompletedNCT00320827Phase 1
• Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917CompletedNCT00290940Phase 2
• Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)TerminatedNCT00272909Phase 2
• Evaluation of the Effects of Carperitide in Patients With Congestive Heart FailureCompletedNCT00259038Phase 2
• Taxoprexin Treatment for Advanced Skin MelanomaCompletedNCT00249262Phase 2
• Taxoprexin® Treatment for Advanced Eye MelanomaCompletedNCT00244816Phase 2
• Pharmacokinetic of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving EpoetinCompletedNCT00239616Phase 2
• Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on DialysisCompletedNCT00236964Phase 3
• Olmesartan as an add-on to Amlodipine in HypertensionCompletedNCT00220233Phase 3
• Amlodipine as add-on to Olmesartan in HypertensionCompletedNCT00220220Phase 3
• Olmesartan Medoxomil in AtherosclerosisCompletedNCT00185185Phase 3
• Olmesartan in Essential HypertensionCompletedNCT00185172Phase 3
• Olmesartan Medoxomil in Diabetes MellitusCompletedNCT00185159Phase 3
• Efficacy and Safety of Pactimibe in Patients With AtherosclerosisCompletedNCT00185146Phase 2
• Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe HypertensionCompletedNCT00185133Phase 3
• Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel BlockerCompletedNCT00185120Phase 4
• Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High CholesterolCompletedNCT00185107Phase 4
• A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to InsulinCompletedNCT00185094Phase 4
• An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With HypertensionCompletedNCT00185068Phase 4
• The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy SubjectsCompletedNCT00185055Phase 4
• Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery DiseaseCompletedNCT00185042Phase 2
• Olmesartan Medoxomil in Hypertension and Renal ImpairmentCompletedNCT00151827Phase 3
• Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.TerminatedNCT00151788Phase 2/3
• Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 DiabetesCompletedNCT00151762Phase 3
• WelChol® and Insulin in Treating Patients With Type 2 DiabetesCompletedNCT00151749Phase 3
• WelChol® and Sulfonylurea in Treating Patients With Type 2 DiabetesCompletedNCT00147758Phase 3
• WelChol® With Metformin in Treating Patients With Type 2 DiabetesCompletedNCT00147719Phase 3
• Placebo and Active Controlled Study of Rivoglitazone in Type 2 DiabetesCompletedNCT00143520Phase 2/3
• Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant MelanomaTerminatedNCT00087776Phase 3
• DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal AdenocarcinomaCompletedNCT00080834Phase 2
• DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT00077077Phase 1
• Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid TumorsWithdrawnNCT00072228Phase 1
• Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00064220Phase 2
• Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT00061854Phase 2
• Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell TumorCompletedNCT00055952Phase 2
• Exatecan Mesylate in Treating Children With Relapsed or Refractory RhabdomyosarcomaCompletedNCT00055939Phase 2
• Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00023972Phase 3
• Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck CancerCompletedNCT00017511Phase 3
• DX-8951f in Treating Patients With Metastatic Stomach CancerCompletedNCT00017212Phase 2
• DX-8951f in Treating Patients With Biliary CancerCompletedNCT00005938Phase 2
• DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerCompletedNCT00005091Phase 2
• DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the CervixCompletedNCT00004866Phase 2
• DX-8951f in Treating Children With Advanced Solid Tumors or LymphomasCompletedNCT00004212Phase 1
• DX-8951f in Treating Patients With Liver CancerCompletedNCT00004108Phase 2
• Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal CancerCompletedNCT00004060Phase 2
• Chemotherapy in Treating Patients Who Have Hematologic CancerCompletedNCT00004047Phase 1
• Chemotherapy in Treating Women With Metastatic Breast CancerCompletedNCT00004046Phase 2
• Chemotherapy in Treating Patients With Prostate CancerCompletedNCT00004045Phase 2
• DX-8951f in Treating Patients With Metastatic Cancer of the PancreasCompletedNCT00003951Phase 2
• A Study of Tecogalan SodiumCompletedNCT00002342Phase 1
• A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.CompletedNCT00002138Phase 1
• A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4CompletedNCT00002137Phase 1
• A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 DaysCompletedNCT00002136Phase 1

← Daiichi Sankyo overview and focus areas